RhoA/Rho-Kinase in the Cardiovascular System

Circulation Research

Volumn 118, Issue 2, 2016, Pages 352-366

  Shimokawa, Hiroaki ^a   Sunamura, Shinichiro ^a   Satoh, Kimio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cardiovascular system; GTP binding protein; inflammation; oxidative stress; rho associated kinases

Indexed keywords

NITRIC OXIDE; PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84955262072     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306532     Document Type: Review

References (240)

1. Vanhoutte PM., Endothelium-derived free radicals: for worse and for better. J Clin Invest 2001, 107:23-25. doi: 10.1172/JCI11832.
2. Shimokawa H., 2014;Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 2014:35;3180-3193. doi: 10.1093/eurheartj/ehu427.
3. Shimokawa H, Satoh K., 2015;ATVB Plenary Lecture: translational research on Rho-kinase in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2015:35;1756-1769. doi: 10.1161/ATVBAHA.115.305353.
4. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K., Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996;15:2208-2216
5. Leung T, Chen XQ, Manser E, Lim L., The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-5327
6. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S., The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996;15:1885-1893
7. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K., Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245-248
8. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K., Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271:20246-20249
9. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC., Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986;232:87-90
10. Griendling KK, Berk BC, Ganz P, Gimbrone MA Jr, Alexander RW., Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. Hypertension 1987;9 III181:III185
11. Berk BC., Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001-81 999 1030
12. Taniyama Y, Griendling KK., Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003;42:1075-1081. doi: 10.1161/01.HYP.0000100443.09293.4F.
13. Ellawindy A, Satoh K, Sunamura S, Rho-kinase Inhibition During Early Cardiac Development Causes Arrhythmogenic Right Ventricular Cardiomyopathy in Mice. Arterioscler Thromb Vasc Biol 2015;35:2172-2184. doi: 10.1161/ATVBAHA.115.305872.
14. Shimokawa H, Takeshita A., Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005;25:1767-1775. doi: 10.1161/01.ATV.0000176193.83629.c8.
15. Etienne-Manneville S, Hall A., Rho GTPases in cell biology. Nature 2002;420:629-635. doi: 10.1038/nature01148.
16. Schmidt A, Hall A., Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 2002;16:1587-1609. doi: 10.1101/gad.1003302.
17. Bernards A., GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003;1603:47-82
18. Olofsson B., Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999;11:545-554
19. Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, Matsuura Y, Seki H, Saida K, Takai Y., Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem 1992;267:8719-8722
20. Wirth A, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind JS, Offermanns S., G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 2008;14:64-68. doi: 10.1038/nm1666.
21. Nishioka T, Shohag MH, Amano M, Kaibuchi K., Developing novel methods to search for substrates of protein kinases such as Rho-kinase. Biochim Biophys Acta 2015;1854:1663-1666. doi: 10.1016/j.bbapap.2015.03.001.
22. Somlyo AP, Somlyo AV., Signal transduction and regulation in smooth muscle. Nature 1994;372:231-236. doi: 10.1038/372231a0.
23. Leung T, Manser E, Tan L, Lim L., A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995;270:29051-29054
24. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S., ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-193
25. Fukata Y, Amano M, Kaibuchi K., Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-39
26. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, Narumiya S., ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168:941-953. doi: 10.1083/jcb.200411179.
27. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM, Narumiya S., Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23:5043-5055
28. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK., ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008;118:1632-1644. doi: 10.1172/JCI29226.
29. Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Ikeda S, Shimokawa H., Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol 2013;33:2780-2791. doi: 10.1161/ATVBAHA.113.301357.
30. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A., Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004;37:537-546. doi: 10.1016/j.yjmcc.2004.05.008.
31. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF., Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001;3; 339-345. doi: 10.1038/35070009.
32. Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breárd J., Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 2005, 201:465-471. doi: 10.1084/jem.20031877.
33. Gabet AS, Coulon S, Fricot A, Vandekerckhove J, Chang Y, Ribeil JA, Lordier L, Zermati Y, Asnafi V, Belaid Z, Debili N, Vainchenker W, Varet B, Hermine O, Courtois G., Caspase-activated ROCK-1 allows erythroblast terminal maturation independently of cytokine-induced Rho signaling. Cell Death Differ 2011;18:678-689. doi: 10.1038/cdd.2010.140.
34. Afonina IS, Cullen SP, Martin SJ., Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 2010;235:105-116. doi: 10.1111/j.0105-2896.2010.00908.x.
35. Hansen SH, Zegers MM, Woodrow M, Rodriguez-Viciana P, Chardin P, Mostov KE, McMahon M., Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-extracellular signal-regulated kinase pathway. Mol Cell Biol 2000;20:9364-9375
36. Nobes CD, Lauritzen I, Mattei MG, Paris S, Hall A, Chardin P., A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J Cell Biol 1998;141:187-197
37. Riento K, Guasch RM, Garg R, Jin B, Ridley AJ., RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol 2003;23:4219-4229
38. Riento K, Totty N, Villalonga P, Garg R, Guasch R, Ridley AJ., RhoE function is regulated by ROCK I-mediated phosphorylation. EMBO J 2005;24:1170-1180. doi: 10.1038/sj.emboj.7600612.
39. Komander D, Garg R, Wan PT, Ridley AJ, Barford D., Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. EMBO J 2008;27:3175-3185. doi: 10.1038/emboj.2008.226.
40. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, Surks HK., ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 2009;104:531-540. doi: 10.1161/CIRCRESAHA.108.188524.
41. Miyazaki K, Komatsu S, Ikebe M., Dynamics of RhoA and ROKα translocation in single living cells. Cell Biochem Biophys 2006;45:243-254. doi: 10.1385/CBB:45:3:243.
42. Pinner S, Sahai E., PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 2008;10:127-137. doi: 10.1038/ncb1675.
43. Loirand G, Guérin P, Pacaud P., Rho-kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-334. doi: 10.1161/01.RES.0000201960.04223.3c.
44. Riento K, Ridley AJ., Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4 446:456. doi: 10.1038/nrm1128.
45. Huveneers S, Daemen MJ, Hordijk PL., Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ Res 2015-116 895 908. doi: 10.1161/CIRCRESAHA.116.305720.
46. Chapados R, Abe K, Ihida-Stansbury K, McKean D, Gates AT, Kern M, Merklinger S, Elliott J, Plant A, Shimokawa H, Jones PL., ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ Res 2006;99:837-844. doi: 10.1161/01.RES.0000246172.77441.f1.
47. van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, van Hinsbergh VW., Involvement of Rho-kinases in endothelial barrier maintenance. Arterioscler Thromb Vasc Biol 2007;27:2332-2339. doi: 10.1161/ATVBAHA.107.152322.
48. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV., Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512-516. doi: 10.1038/nature11087.
49. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Araki H, Nakamura M, Ishii Y, Tanaka K., Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983;221:560-562
50. Shimokawa H., Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999;31:23-37. doi: 10.1006/jmcc.1998.0841.
51. Berk BC., Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. Circulation 2008;117:1082-1089. doi: 10.1161/CIRCULATIONAHA.107.720730.
52. Nigro P, Abe J, Woo CH, Satoh K, McClain C, O'Dell MR, Lee H, Lim JH, Li JD, Heo KS, Fujiwara K, Berk BC., PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood 2010;116:1971-1979. doi: 10.1182/blood-2010-02-269134.
53. Abe J, Berk BC., Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis. Circulation 2013;128:579-582. doi: 10.1161/CIRCULATIONAHA.113.004390.
54. Nigro P, Abe J, Berk BC., Flow shear stress and atherosclerosis: a matter of site specificity. Antioxid Redox Signal 2011;15:1405-1414. doi: 10.1089/ars.2010.3679.
55. Zhou Q, Liao JK., Rho-kinases: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009;15:3108-3115
56. Yao L, Chandra S, Toque HA, Bhatta A, Rojas M, Caldwell RB, Caldwell RW., Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho-kinases (ROCK) knockout. Cardiovasc Res 2013;97:509-519. doi: 10.1093/cvr/cvs371.
57. Noda K, Godo S, Saito H, Tsutsui M, Shimokawa H., Opposing roles of nitric oxide and Rho-kinase in lipid metabolism in mice. Tohoku J Exp Med 2015;235:171-183. doi: 10.1620/tjem.235.171.
58. Noda K, Nakajima S, Godo S, Saito H, Ikeda S, Shimizu T, Enkhjargal B, Fukumoto Y, Tsukita S, Yamada T, Katagiri H, Shimokawa H., Rho-kinase inhibition ameliorates metabolic disorders through activation of AMPK pathway in mice. PLoS One 2014;9 e110446. doi: 10.1371/journal.pone.0110446.
59. Takemoto M, Liao JK., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001:21-1712 1719
60. Tanaka S, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, Takai Y, Williams CL, Liao JK, Shimokawa H., Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol 2013;33:1591-1600. doi: 10.1161/ATVBAHA.112.300922.
61. Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J., Redox modification of cell signaling in the cardiovascular system. J Mol Cell Cardiol 2012;52:550-558. doi: 10.1016/j.yjmcc.2011.09.009.
62. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A., Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000;106:1521-1530. doi: 10.1172/JCI10506.
63. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, Hatanaka M, Fujiki T, Maeda H, Takahashi S, Takeshita A., Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest 2003;112:1871-1879. doi: 10.1172/JCI19351.
64. Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H, Ohashi J, Yada T, Yanagihara N, Shimokawa H., Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008;205:2053-2063. doi: 10.1084/jem.20080106.
65. Takaki A, Morikawa K, Murayama Y, Yamagishi H, Hosoya M, Ohashi J, Shimokawa H., Roles of endothelial oxidases in endothelium-derived hyperpolarizing factor responses in mice. J Cardiovasc Pharmacol 2008;52:510-517. doi: 10.1097/FJC.0b013e318190358b.
66. Cohen RA, Adachi T., Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med 2006;16:109-114. doi: 10.1016/j.tcm.2006.02.001.
67. Wu C, Parrott AM, Fu C, Liu T, Marino SM, Gladyshev VN, Jain MR, Baykal AT, Li Q, Oka S, Sadoshima J, Beuve A, Simmons WJ, Li H., Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. Antioxid Redox Signal 2011;15:2565-2604. doi: 10.1089/ars.2010.3831.
68. Spindel ON, Burke RM, Yan C, Berk BC., Thioredoxin-interacting protein is a biomechanical regulator of Src activity: key role in endothelial cell stress fiber formation. Circ Res 2014;114:1125-1132. doi: 10.1161/CIRCRESAHA.114.301315.
69. Park SY, Shi X, Pang J, Yan C, Berk BC., Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells required for angiogenesis. Arterioscler Thromb Vasc Biol 2013;33:737-743. doi: 10.1161/ATVBAHA.112.300386.
70. Yamawaki H, Pan S, Lee RT, Berk BC., Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 2005;115:733-738. doi: 10.1172/JCI23001.
71. Wang XQ, Nigro P, World C, Fujiwara K, Yan C, Berk BC., Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2. Circ Res 2012;110:560-568. doi: 10.1161/CIRCRESAHA.111.256362.
72. Ishida T, Ishida M, Suero J, Takahashi M, Berk BC., Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J Clin Invest 1999;103:789-797. doi: 10.1172/JCI4189.
73. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, Dimmeler S., Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 2002;4 743:749. doi: 10.1038/ncb851.
74. Shimokawa H, Satoh K., Light and dark of reactive oxygen species for vascular function: 2014;ASVB (Asian Society of Vascular Biology). J Cardiovasc Pharmacol 2015:65-412 418. doi: 10.1097/FJC.0000000000000159.
75. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M., Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009;196:193-222. doi: 10.1111/j.1748-1716.2009.01964.x.
76. Shimokawa H., Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch 2010;459:915-922. doi: 10.1007/s00424-010-0790-8.
77. Chen G, Suzuki H, Weston AH., Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 1988;95:1165-1174
78. Prysyazhna O, Rudyk O, Eaton P., Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med 2012;18:286-290. doi: 10.1038/nm.2603.
79. Félétou M, Vanhoutte PM., Endothelium-dependent hyperpolarizations: past beliefs and present facts. Ann Med 2007;39:495-516. doi: 10.1080/07853890701491000.
80. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schröder E, Browning DD, Eaton P., Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007;317:1393-1397. doi: 10.1126/science.1144318.
81. Burgoyne JR, Prysyazhna O, Rudyk O, Eaton P., cGMP-dependent activation of protein kinase G precludes disulfide activation: implications for blood pressure control. Hypertension 2012;60:1301-1308. doi: 10.1161/HYPERTENSIONAHA.112.198754.
82. Ohashi J, Sawada A, Nakajima S, Noda K, Takaki A, Shimokawa H., Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. Circ J 2012;76:1768-1779
83. Nakajima S, Ohashi J, Sawada A, Noda K, Fukumoto Y, Shimokawa H., Essential role of bone marrow for microvascular endothelial and metabolic functions in mice. Circ Res 2012;111:87-96. doi: 10.1161/CIRCRESAHA.112.270215.
84. Streb H, Irvine RF, Berridge MJ, Schulz I., Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 1983;306:67-69
85. Berridge MJ., Smooth muscle cell calcium activation mechanisms. J Physiol 2008;586:5047-5061. doi: 10.1113/jphysiol.2008.160440.
86. Ikebe M, Hartshorne DJ., Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase. J Biol Chem 1985;260:10027-10031
87. Seto M, Sasaki Y, Sasaki Y., Stimulus-specific patterns of myosin light chain phosphorylation in smooth muscle of rabbit thoracic artery. Pflugers Arch 1990;415:484-489
88. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A., Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999;43:1029-1039
89. Cai Y, Nagel DJ, Zhou Q, Cygnar KD, Zhao H, Li F, Pi X, Knight PA, Yan C., Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia. Circ Res 2015;116:1120-1132. doi: 10.1161/CIRCRESAHA.116.304408.
90. Satoh K, Kikuchi N, Kurosawa R, Shimokawa H., PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circ Res 2015;116:1098-1100. doi: 10.1161/CIRCRESAHA.115.306139.
91. Fukumoto Y, Shimokawa H, Ito A, Kadokami T, Yonemitsu Y, Aikawa M, Owada MK, Egashira K, Sueishi K, Nagai R, Yazaki Y, Takeshita A., Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. J Cardiovasc Pharmacol 1997;29:222-231
92. Seto M, Yano K, Sasaki Y, Azuma H., Intimal hyperplasia enhances myosin phosphorylation in rabbit carotid artery. Exp Mol Pathol 1993;58:1 13. doi: 10.1006/exmp.1993.1001.
93. Kitazawa T, Masuo M, Somlyo AP., G protein-mediated inhibition of myosin light-chain phosphatase in vascular smooth muscle. Proc Natl Acad Sci USA 1991-88 9307 9310
94. Gong MC, Iizuka K, Nixon G, Browne JP, Hall A, Eccleston JF, Sugai M, Kobayashi S, Somlyo AV, Somlyo AP., Role of guanine nucleotide-binding proteins-ras-family or trimeric proteins or both-in Ca2+ sensitization of smooth muscle. Proc Natl Acad Sci USA 1996;93:1340-1345
95. Alessi D, MacDougall LK, Sola MM, Ikebe M, Cohen P., The control of protein phosphatase-1 by targetting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Eur J Biochem 1992;210:1023-1035
96. Shimizu H, Ito M, Miyahara M, Ichikawa K, Okubo S, Konishi T, Naka M, Tanaka T, Hirano K, Hartshorne DJ., Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J Biol Chem 1994;269:30407-30411
97. Chihara K, Amano M, Nakamura N, Yano T, Shibata M, Tokui T, Ichikawa H, Ikebe R, Ikebe M, Kaibuchi K., Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem 1997;272:25121-25127
98. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M., Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997;272:12257-12260
99. Amano M, Chihara K, Nakamura N, Fukata Y, Yano T, Shibata M, Ikebe M, Kaibuchi K., Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells 1998;3,177-188
100. Alexander RW., Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995-25 155 161
101. Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS., Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and-independent nitrovasodilator relaxation. Circ Res 1991;69:601-608
102. Baas AS, Berk BC., Differential activation of mitogen-activated protein kinases by H2O2 and O2-in vascular smooth muscle cells. Circ Res 1995;77:29-36
103. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW., Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148
104. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A., Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93:767-775. doi: 10.1161/01.RES.0000096650.91688.28.
105. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW., Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho-kinase and protein tyrosine kinases. Circ Res 2000;87:335-340
106. Kishi H, Bao J, Kohama K., Inhibitory effects of ML-9, wortmannin, and Y-27632;on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem 2000:128-719 722
107. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Vaillant N, Gadeau AP, Desgranges C, Scalbert E, Chardin P, Pacaud P, Loirand G., P2Y(1), P2Y(2), P2Y(4), and P2Y(6) receptors are coupled to Rho and Rho-kinase activation in vascular myocytes. Am J Physiol Heart Circ Physiol 2000;278:H1751-H1761
108. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G., Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-1104
109. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC., Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 2006;98:811-817. doi: 10.1161/01.RES.0000216405.85080.a6.
110. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, Mohan A, Pan S, Li L, Jin ZG, Yan C, Abe J, Berk BC., Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008;117:3088-3098. doi: 10.1161/CIRCULATIONAHA.107.756106.
111. Shimokawa H., Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 2000;64:1 12
112. Shimokawa H., Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002-39 319 327
113. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K., Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997;275:1308-1311
114. Wang J, Weigand L, Foxson J, Shimoda LA, Sylvester JT., Ca2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho-kinase antagonists. Am J Physiol Lung Cell Mol Physiol 2007;293:L674-L685. doi: 10.1152/ajplung.00141.2007.
115. Satoh K, Godo S, Saito H, Enkhjargal B, Shimokawa H., Dual roles of vascular-derived reactive oxygen species-with a special reference to hydrogen peroxide and cyclophilin A. J Mol Cell Cardiol 2014;73:50-56. doi: 10.1016/j.yjmcc.2013.12.022.
116. Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R., Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001;88:44-51
117. Lassègue B, San Martín A, Griendling KK., Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012;110:1364-1390. doi: 10.1161/CIRCRESAHA.111.243972.
118. Nishida M, Hara Y, Yoshida T, Inoue R, Mori Y., TRP channels: molecular diversity and physiological function. Microcirculation 2006;13:535-550. doi: 10.1080/10739680600885111.
119. Shimizu S, Takahashi N, Mori Y., TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters). Handb Exp Pharmacol 2014;223:767-794. doi: 10.1007/978-3-319-05161-1-3.
120. Vanhoutte PM., Say NO to ET. J Auton Nerv Syst 2000;81:271-277
121. Yang D, Félétou M, Boulanger CM, Wu HF, Levens N, Zhang JN, Vanhoutte PM., Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 2002;136:104-110. doi: 10.1038/sj.bjp.0704669.
122. Shimokawa H., Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res 2013;113:1040-1042. doi: 10.1161/CIRCRESAHA.113.302049.
123. Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K, Shimokawa H., Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009;81:226-234. doi: 10.1093/cvr/cvn244.
124. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis JD, Sparks JD, Berk BC., Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011;208:53-66. doi: 10.1084/jem.20101174.
125. Shimokawa H, Rashid M., Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28:296-302. doi: 10.1016/j.tips.2007.04.006.
126. Satoh K, Fukumoto Y, Shimokawa H., Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011;301:H287-H296. doi: 10.1152/ajpheart.00327.2011.
127. Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, Amano M, Hoshijima M, Kaibuchi K, Takeshita A., Gene transfer of dominant negative Rho-kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 2000;278:H1744-H1750
128. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K., Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000;101:2030-2033
129. Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T., Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 2001;103:284-289
130. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, Egashira K, Kaibuchi K, Takeshita A., Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 2000;20:2351-2358
131. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A., Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996;97:769-776. doi: 10.1172/JCI118476.
132. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, Takeshita A., Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 2001;51:169-177
133. Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, Shibata Y, Matsuda T, Takeshita A, Shimokawa H., Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004;24:181-186. doi: 10.1161/01.ATV.0000105053.46994.5B.
134. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A., Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004;109:2234-2239. doi: 10.1161/01.CIR.0000127939.16111.58.
135. Radeff JM, Nagy Z, Stern PH., Rho and Rho-kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J Bone Miner Res 2004;19:1882-1891. doi: 10.1359/JBMR.040806.
136. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, Takeshita A., Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001;38:100-104
137. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A., Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004;94:46-52. doi: 10.1161/01.RES.0000107196.21335.2B.
138. Wang F, Okamoto Y, Inoki I, Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest 2010;120:3979-3995. doi: 10.1172/JCI42315.
139. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK., Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57-62
140. Oi K, Shimokawa H, Hiroki J, Uwatoku T, Abe K, Matsumoto Y, Nakajima Y, Nakajima K, Takeichi S, Takeshita A., Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler Thromb Vasc Biol 2004;24:918-922. doi: 10.1161/01.ATV.0000126678.93747.80.
141. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD, Berk BC., Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000;87:789-796
142. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, Berk BC., Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000;275:189-196
143. Satoh K., Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med 2015;235:1-15. doi: 10.1620/tjem.235.1.
144. Satoh K, Nigro P, Berk BC., Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal 2010,12, 675-682. doi: 10.1089/ars.2009.2875.
145. Satoh K, Shimokawa H, Berk BC., Cyclophilin A: promising new target in cardiovascular therapy. Circ J 2010;74:2249-2256
146. Mackay DJ, Hall A., Rho GTPases. J Biol Chem 1998;273:20685-20688
147. Neco P, Giner D, Viniegra S, Borges R, Villarroel A, Gutiérrez LM., New roles of myosin II during vesicle transport and fusion in chromaffin cells. J Biol Chem 2004;279:27450-27457. doi: 10.1074/jbc.M311462200.
148. Damsker JM, Bukrinsky MI, Constant SL., Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 2007;82:613-618. doi: 10.1189/jlb.0506317.
149. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P., Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1299-1310. doi: 10.1093/rheumatology/ken225.
150. Elvers M, Herrmann A, Seizer P, Münzer P, Beck S, Schönberger T, Borst O, Martin-Romero FJ, Lang F, May AE, Gawaz M., Intracellular cyclophilin A is an important Ca2+ regulator in platelets and critically involved in arterial thrombus formation. Blood 2012;120:1317-1326. doi: 10.1182/blood-2011-12-398438.
151. Seizer P, Ungern-Sternberg SN, Schönberger T, Borst O, Münzer P, Schmidt EM, Mack AF, Heinzmann D, Chatterjee M, Langer H, Malešević M, Lang F, Gawaz M, Fischer G, May AE., Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2015;35:655-663. doi: 10.1161/ATVBAHA.114.305112.
152. Seizer P, Gawaz M, May AE., Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases. Cardiovasc Res 2014;102:17-23. doi: 10.1093/cvr/cvu035.
153. Eto M, Barandiér C, Rathgeb L, Kozai T, Joch H, Yang Z, Lüscher TF., Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001;89:583-590
154. Soe NN, Sowden M, Baskaran P, Smolock EM, Kim Y, Nigro P, Berk BC., Cyclophilin A is required for angiotensin II-induced p47phox translocation to caveolae in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2013;33:2147-2153. doi: 10.1161/ATVBAHA.113.301894.
155. Pushkarsky T, Zybarth G, Dubrovsky L, Yurchenko V, Tang H, Guo H, Toole B, Sherry B, Bukrinsky M., CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci USA 2001;98:6360-6365. doi: 10.1073/pnas.111583198.
156. Satoh K, Satoh T, Kikuchi N, Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. Circ Res 2014;115:738-750. doi: 10.1161/CIRCRESAHA.115.304563.
157. Weintraub NL., Understanding abdominal aortic aneurysm. N Engl J Med 2009;361:1114-1116. doi: 10.1056/NEJMcibr0905244.
158. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994. doi: 10.1038/40187.
159. Hirooka Y, Shimokawa H, Takeshita A., Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect 2004;17:523-527
160. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A., Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001;15:1062-1064
161. Haack KK, Gao L, Schiller AM, Curry PL, Pellegrino PR, Zucker IH., Central Rho-kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure. Hypertension 2013;61:723-729. doi: 10.1161/HYPERTENSIONAHA.111.00396.
162. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, Takeshita A., Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 2003;92:1337-1343. doi: 10.1161/01.RES.0000079941.59846.D4.
163. Zamanian RT, Kudelko KT, Sung YK, de Jesus Perez V, Liu J, Spiekerkoetter E., Current clinical management of pulmonary arterial hypertension. Circ Res 2014;115:131-147. doi: 10.1161/CIRCRESAHA.115.303827.
164. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR., Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014;115:165-175. doi: 10.1161/CIRCRESAHA.113.301141.
165. Paulin R, Michelakis ED., The metabolic theory of pulmonary arterial hypertension. Circ Res 2014;115:148-164. doi: 10.1161/CIRCRESAHA.115.301130.
166. Michelakis ED., Pulmonary arterial hypertension: yesterday, today, tomorrow. Circ Res 2014;115:109-114. doi: 10.1161/CIRCRESAHA.115.301132.
167. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT., Pulmonary arterial hypertension: the clinical syndrome. Circ Res 2014;115:115-130. doi: 10.1161/CIRCRESAHA.115.301146.
168. Austin ED, Loyd JE., The genetics of pulmonary arterial hypertension. Circ Res 2014;115:189-202. doi: 10.1161/CIRCRESAHA.115.303404.
169. Fukumoto Y, Shimokawa H., Rho-kinase inhibitors. Handb Exp Pharmacol 2013;218:351-363. doi: 10.1007/978-3-642-38664-0-14.
170. Stenmark KR, Fagan KA, Frid MG., Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-691. doi: 10.1161/01.RES.0000243584.45145.3f.
171. Satoh K, Kagaya Y, Nakano M, Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006;113:1442-1450. doi: 10.1161/CIRCULATIONAHA.105.583732.
172. Elias-Al-Mamun M, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H., Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J 2014;78:967-976
173. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y, Shimokawa H., Crucial role of Rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol 2014;34:1260-1271. doi: 10.1161/ATVBAHA.114.303320.
174. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC., Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:1186-1191. doi: 10.1161/01.ATV.0000130664.51010.28.
175. Khromykh LM, Kulikova NL, Anfalova TV, Muranova TA, Abramov VM, Vasiliev AM, Khlebnikov VS, Kazansky DB., Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol 2007;249:46-53. doi: 10.1016/j.cellimm.2007.11.002.
176. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A., Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-393. doi: 10.1161/01.RES.0000111804.34509.94.
177. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H., Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006;48:280-285. doi: 10.1097/01.fjc.0000248244.64430.4a.
178. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H., Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009;73:1731-1739
179. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H., Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-392. doi: 10.1136/hrt.2003.029470.
180. Fukumoto Y, Yamada N, Matsubara H, Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 2013;77:2619-2625
181. Dhaliwal JS, Casey DB, Greco AJ, Badejo AM Jr, Gallen TB, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ., Rho-kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. Am J Physiol Lung Cell Mol Physiol 2007;293:L1306-L1313. doi: 10.1152/ajplung.00189.2007.
182. Rao GN, Berk BC., Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70:593-599
183. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Eto Y, Morishige K, Matsumoto Y, Obara K, Nakayama K, Takahashi S, Takeshita A., Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol 2003;23:2209-2214. doi: 10.1161/01.ATV.0000104010.87348.26.
184. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T., Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000;35:313-318
185. Shimokawa H., Bone-marrow-derived matrix metalloproteinase-14: a novel target for plaque stability. Circulation 2008;117:863-865. doi: 10.1161/CIRCULATIONAHA.107.756346.
186. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A., Involvement of Rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 2002;22:243-248
187. Sawada N, Liao JK., Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal 2014;20:1251-1267. doi: 10.1089/ars.2013.5524.
188. Takagi Y, Yasuda S, Takahashi J, Takeda M, Nakayama M, Ito K, Hirose M, Wakayama Y, Fukuda K, Shimokawa H., Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest. Circ J 2009;73:767-769
189. Hizume T, Morikawa K, Takaki A, Abe K, Sunagawa K, Amano M, Kaibuchi K, Kubo C, Shimokawa H., Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm. Circ Res 2006;99:767-775. doi: 10.1161/01.RES.0000244093.69985.2f.
190. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, Takeshita A., Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 2000;101:1319-1323
191. Katsumata N, Shimokawa H, Seto M, Kozai T, Yamawaki T, Kuwata K, Egashira K, Ikegaki I, Asano T, Sasaki Y, Takeshita A., Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 1997;96:4357-4363
192. Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, Nakaike R, Takayanagi T, Egashira K, Takeshita A., Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest 1995;96:1288-1294. doi: 10.1172/JCI118163.
193. Libby P., Inflammation in atherosclerosis. Nature 2002;420:868-874. doi: 10.1038/nature01323.
194. Kunieda T, Minamino T, Nishi J, Tateno K, Oyama T, Katsuno T, Miyauchi H, Orimo M, Okada S, Takamura M, Nagai T, Kaneko S, Komuro I., Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006;114:953-960. doi: 10.1161/CIRCULATIONAHA.106.626606.
195. Griendling KK, FitzGerald GA., Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003;108:2034-2040. doi: 10.1161/01.CIR.0000093661.90582.c4.
196. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA., Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003;112:1318-1331. doi: 10.1172/JCI18141.
197. Daugherty A, Manning MW, Cassis LA., Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105:1605-1612. doi: 10.1172/JCI7818.
198. Daugherty A, Cassis L., Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004;14:117-120. doi: 10.1016/j.tcm.2004.01.002.
199. Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA, Dellsperger KC, Weintraub NL., Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006;114:404-413. doi: 10.1161/CIRCULATIONAHA.105.607168.
200. Gavazzi G, Deffert C, Trocme C, Schäppi M, Herrmann FR, Krause KH., NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 2007;50:189-196. doi: 10.1161/HYPERTENSIONAHA.107.089706.
201. Thompson RW, Baxter BT., MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999;878:159-178
202. Manning MW, Cassis LA, Daugherty A., Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003;23:483-488. doi: 10.1161/01.ATV.0000058404.92759.32.
203. Wang YX, Martin-McNulty B, da Cunha V, Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 2005;111:2219-2226. doi: 10.1161/01.CIR.0000163544.17221.BE.
204. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC., Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009;15:649-656. doi: 10.1038/nm.1958.
205. Mehta PK, Griendling KK., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97. doi: 10.1152/ajpcell.00287.2006.
206. Sadoshima J, Xu Y, Slayter HS, Izumo S., Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-984
207. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M., Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 1998;98:794-799
208. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM., NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 2009;47:15-22. doi: 10.1016/j.yjmcc.2009.04.004.
209. Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ., Functional effects of Rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res 2005;96:740-747. doi: 10.1161/01.RES.0000162457.56568.7d.
210. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H., Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008;51:317-326. doi: 10.1097/FJC.0b013e31816533b7.
211. Takimoto E, Kass DA., Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-248. doi: 10.1161/01.HYP.0000254415.31362.a7.
212. Satoh K, Nigro P, Zeidan A, Soe NN, Jaffré F, Oikawa M, O'Dell MR, Cui Z, Menon P, Lu Y, Mohan A, Yan C, Blaxall BC, Berk BC., Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011;31:1116-1123. doi: 10.1161/ATVBAHA.110.214601.
213. Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Tanaka E, Shinozaki Y, Mori H, Kiyooka T, Katsura M, Ohkuma S, Goto M, Ogasawara Y, Kajiya F., Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol 2005;45:599-607. doi: 10.1016/j.jacc.2004.10.053.
214. Sato S, Ikegaki I, Asano T, Shimokawa H., Antiischemic properties of fasudil in experimental models of vasospastic angina. Jpn J Pharmacol 2001;87:34-40
215. Utsunomiya T, Satoh S, Ikegaki I, Toshima Y, Asano T, Shimokawa H., Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol 2001;134:1724-1730. doi: 10.1038/sj.bjp.0704410.
216. Satoh Si, Ikegaki I, Toshima Y, Watanabe A, Asano T, Shimokawa H., Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. Life Sci 2002;72:103-112
217. Zoccarato A, Surdo NC, Aronsen JM, Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2. Circ Res 2015;117:707-719. doi: 10.1161/CIRCRESAHA.114.305892.
218. Ryan JJ, Archer SL., The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014;115:176-188. doi: 10.1161/CIRCRESAHA.113.301129.
219. Takefuji M, Krüger M, Sivaraj KK, Kaibuchi K, Offermanns S, Wettschureck N., RhoGEF12 controls cardiac remodeling by integrating G protein-and integrin-dependent signaling cascades. J Exp Med 2013;210:665-673. doi: 10.1084/jem.20122126.
220. Brakebusch C, Fässler R., The integrin-actin connection, an eternal love affair. EMBO J 2003;22:2324-2333. doi: 10.1093/emboj/cdg245.
221. Zhao XH, Laschinger C, Arora P, Szászi K, Kapus A, McCulloch CA., Force activates smooth muscle α-actin promoter activity through the Rho signaling pathway. J Cell Sci 2007;120:1801-1809. doi: 10.1242/jcs.001586.
222. Shibata R, Ouchi N, Murohara T., Adiponectin and cardiovascular disease. Circ J 2009;73:608-614
223. Gillers BS, Chiplunkar A, Aly H, Valenta T, Basler K, Christoffels VM, Efimov IR, Boukens BJ, Rentschler S., Canonical Wnt signaling regulates atrioventricular junction programming and electrophysiological properties. Circ Res 2015;116:398-406. doi: 10.1161/CIRCRESAHA.116.304731.
224. Delmar M, McKenna WJ., The cardiac desmosome and arrhythmogenic cardiomyopathies: from gene to disease. Circ Res 2010;107:700-714. doi: 10.1161/CIRCRESAHA.110.223412.
225. Awad MM, Calkins H, Judge DP., Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008;5 258:267. doi: 10.1038/ncpcardio1182.
226. Corrado D, Basso C, Pilichou K, Thiene G., Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011-97 530 539. doi: 10.1136/hrt.2010.193276.
227. Amano M, Fukata Y, Kaibuchi K., Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261:44-51. doi: 10.1006/excr.2000.5046.
228. Cristancho AG, Lazar MA., Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011;12:722-734. doi: 10.1038/nrm3198.
229. Schlessinger K, Hall A, Tolwinski N., Wnt signaling pathways meet Rho GTPases. Genes Dev 2009;23:265-277. doi: 10.1101/gad.1760809.
230. Angers S, Moon RT., Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009;10:468-477. doi: 10.1038/nrm2717.
231. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ., Suppression of canonical Wnt/β-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006;116:2012-2021. doi: 10.1172/JCI27751.
232. Lombardi R, Dong J, Rodriguez G, Bell A, Leung TK, Schwartz RJ, Willerson JT, Brugada R, Marian AJ., Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2009;104:1076-1084. doi: 10.1161/CIRCRESAHA.109.196899.
233. Lombardi R, da Graca Cabreira-Hansen M, Bell A, Fromm RR, Willerson JT, Marian AJ., Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2011;109:1342-1353. doi: 10.1161/CIRCRESAHA.111.255075.
234. Marcus FI, McKenna WJ, Sherrill D, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533-1541. doi: 10.1161/CIRCULATIONAHA.108.840827.
235. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H., Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241:1033-1040
236. Davies SP, Reddy H, Caivano M, Cohen P., Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105
237. Akama T, Dong C, Virtucio C, Freund YR, Chen D, Orr MD, Jacobs RT, Zhang YK, Hernandez V, Liu Y, Wu A, Bu W, Liu L, Jarnagin K, Plattner JJ., Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents. Bioorg Med Chem Lett 2013;23:5870-5873. doi: 10.1016/j.bmcl.2013.08.096.
238. Akama T, Dong C, Virtucio C, Sullivan D, Zhou Y, Zhang YK, Rock F, Freund Y, Liu L, Bu W, Wu A, Fan XQ, Jarnagin K., Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency Rho-kinase inhibitors. J Pharmacol Exp Ther 2013;347:615-625. doi: 10.1124/jpet.113.207662.
239. Irani RA, Xia Y., The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 2008;29:763-771. doi: 10.1016/j.placenta.2008.06.011.
240. Wei L, Roberts W, Wang L, Yamada M, Zhang S, Zhao Z, Rivkees SA, Schwartz RJ, Imanaka-Yoshida K., Rho-kinase play an obligatory role in vertebrate embryonic organogenesis. Development 2001;128:2953-2962